Claude
The Full Story
Religare Enterprises is a decade-long turnaround story that has passed through three distinct regimes: the Singh brothers' era of empire-building and eventual fraud (pre-2018), the Rashmi Saluja period of defensive stabilization and debt resolution (2018-2025), and the Burman Group's arrival as promoters with a mandate to professionalize and demerge (February 2025 onward). The core narrative changed from "diversified financial conglomerate" to "fraud recovery vehicle" to, most recently, "platform ready for re-launch." Management credibility is resetting under new ownership, but the group has yet to prove it can grow profitably – Care Health Insurance remains the only business that has consistently delivered, while the rest are either sub-scale or just restarting.
1. The Narrative Arc
The most striking aspect of this timeline is how long the recovery took. From RBI's corrective action in January 2018 to the lift of CAP in July 2025 – seven and a half years of business freeze at the NBFC. The Singh brothers' fraud created a wound so deep that even after full debt settlement (FY23), it took two more years of regulatory clearing before RFL could contemplate restarting lending.
Revenue recovered past the FY2014 peak only in FY2024, driven almost entirely by Care Health Insurance premium growth. Operating income remains thin and volatile, reflecting that the group's profitability engine is singular – CHIL accounts for the vast majority of revenue and all of the recurring profit.
2. What Management Emphasized – and Then Stopped Emphasizing
Dropped themes: The "360-degree financial services conglomerate" language, prominent in the Saluja era (FY2022-FY2023), disappeared entirely after the Burman Group takeover. The new management speaks of "focused entities" and "separate listings." Rashmi Saluja herself went from being the face of every annual report to being named only in the context of SEBI proceedings and ESOP cancellation orders post-February 2025.
Quiet pivots: MIC Insurance Web Aggregator, acquired in December 2023 as a "strategic step in REL's growth trajectory," was suspended within 18 months due to "sub-optimal business operations and continued decline in net worth." This acquisition was never meaningfully discussed on any earnings call.
Persistent theme: Care Health Insurance has been the one constant positive narrative across all management regimes – it is the asset that survived the fraud, survived the promoter wars, and keeps growing.
3. Risk Evolution
The risk profile has undergone a dramatic shift. Legacy risks (fraud cleanup, RBI CAP, debt restructuring) have largely been resolved. But new execution risks have emerged: can RFL actually restart lending after a 7-year hiatus with a Rs 70 Cr residual book and no lending lines? Can the demerger be executed in 15-18 months as promised? The Daiichi litigation around the "Religare" brand and the SEBI proceedings against the former chairperson remain unresolved overhangs.
The RBI dividend restriction (in place since April 2019) remains active. This means shareholders have received zero dividends across the entire recovery arc despite the P/E ratio sitting at 72.8x. The valuation is entirely on future expectations.
4. How They Handled Bad News
The RFL fraud discovery (2018): The new management was forthcoming about the scale of damage – Rs 2,037 Cr siphoned through Corporate Loan Book, Rs 791 Cr of fixed deposits misappropriated by Lakshmi Vilas Bank. Annual reports repeatedly spelled out these figures. However, the "revival" narrative was consistently optimistic about timelines, with the Debt Restructuring Plan announced in FY2021 not completing until March 2023.
The SEBI interim order (June 2024): When SEBI issued its show cause notice alleging that REL failed to facilitate the Burman open offer, the company framed this as regulatory compliance rather than governance failure. The SAT appeal was subsequently withdrawn in July 2025, and the company then filed with SEBI seeking "appropriate action against Noticee No. 2 i.e. erstwhile Executive Chairperson" – a sharp public distancing from Rashmi Saluja.
MIC Insurance Aggregator failure: Acquired in December 2023 with fanfare ("crucial step in REL's growth trajectory"), suspended in FY2025 due to "sub-optimal business operations." The FY2025 annual report acknowledges this was partly because the company "could not raise funds for MIC through equity capital infusion" during the open offer period. No estimate of write-off provided in narrative.
5. Guidance Track Record
Management Credibility Score
Score: 4 out of 10. The Saluja-era management delivered on the existential tasks (debt settlement, fraud tag removal) but consistently overestimated timelines and quietly abandoned the conglomerate narrative. The Burman-era team is too new to have a track record – the November 2025 call was their first public engagement. The credibility score reflects: legacy promises were broadly kept but always late; the MIC acquisition was a clear mis-step; and the current team has made ambitious structural commitments (demerger, Rs 1,500 Cr raise, RFL restart) that remain unproven. CHIL performance is the one area where delivery has been consistent.
6. What the Story Is Now
FY25 Revenue (Rs Cr)
FY25 Op. Income (Rs Cr)
P/E Ratio
The story today is a bet on three things happening simultaneously:
1. Care Health Insurance continues compounding. CHIL is the crown jewel – second-largest standalone health insurer, GWP growing 20%+ annually, consistently profitable since FY19, investment book crossing Rs 10,000 Cr. This business alone justifies serious attention. The demerger will eventually make REL a pure-play insurance holding company.
2. RFL actually restarts. After seven years of dormancy, RFL has Rs 800 Cr net worth, 228% CRAR, zero debt – and a Rs 70 Cr loan book. The stated plan is to lever up to "industry standards" over the next couple of years targeting MSME lending. But the lending infrastructure, IT systems, banking lines, and team all need to be rebuilt. The market is pricing in a successful restart that has not yet begun.
3. The demerger unlocks the holdco discount. The February 2026 announcement of financial services demerger into RFL (with 1:1 share issuance) is the clearest structural value-unlock step management has taken. If executed on the stated 15-18 month timeline, RFL would list by Q1 FY28. This creates two focused entities – but the history of Indian demergers suggests timelines regularly slip.
What to discount: The 72.8x P/E reflects expectations well beyond current earnings power. RBI still prohibits dividends. Only Rs 410 Cr of Rs 1,500 Cr warrants have been converted. The "Religare" brand itself is subject to Daiichi litigation. Two of four subsidiaries (RFL, RHDFCL) are currently loss-making or subscale. The entire investment thesis rests on execution that is directionally right but unproven under this management.
What has been de-risked: Fraud tags fully removed. RBI CAP lifted. Debt fully settled (Rs 9,200 Cr+ repaid to banking system). Promoter clarity established with Burman Group. Board professionally reconstituted. CHIL has seven years of continuous profitability.
The honest reading is that Religare today is a holding company whose value is almost entirely CHIL, wrapped in a turnaround narrative that has finally cleared its regulatory obstacles. The next 18 months will determine whether this becomes a genuine multi-business financial platform or remains a health insurance company with expensive legacy overhead.